Oncternal Therapeutics (NASDAQ:ONCT) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note issued to investors on Friday. The firm issued a hold rating on the stock.

Several other research firms also recently commented on ONCT. Brookline Capital Management reissued a “hold” rating on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Northland Capmk downgraded shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. Finally, Northland Securities reissued a “market perform” rating and set a $2.00 price target on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $10.00.

Oncternal Therapeutics Price Performance

Shares of Oncternal Therapeutics stock opened at $0.53 on Friday. Oncternal Therapeutics has a 1 year low of $0.53 and a 1 year high of $13.14. The firm has a market cap of $1.56 million, a PE ratio of -0.05 and a beta of 1.18. The company has a 50 day simple moving average of $1.12 and a two-hundred day simple moving average of $3.97.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC bought a new position in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned 0.84% of Oncternal Therapeutics as of its most recent SEC filing. Institutional investors own 16.05% of the company’s stock.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.